

Welcome to STN International! Enter x:x

LOGINID:sssptal600dxk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on
STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:17:12 ON 20 JAN 2003

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:17:19 ON 20 JAN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2003 HIGHEST RN 479481-27-1
 DICTIONARY FILE UPDATES: 19 JAN 2003 HIGHEST RN 479481-27-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e paclitaxel/cn

E1	1	PACKY N 50/CN
E2	1	PACKZOL/CN
E3	1 -->	PACLITAXEL/CN
E4	1	PACLITAXEL 2'-(ALL-CIS-4,7,10,13,16,19-DOCOSAHEXAENOATE)/CN
E5	1	PACLITAXEL 6.ALPHA.-HYDROXYLASE/CN
E6	1	PACLITAXEL 6.ALPHA.-MONOOXYGENASE/CN
E7	1	PACLITAXEL 7-(ALL-CIS-4,7,10,13,16,19-DOCOSAHEXAENOATE)/CN
E8	1	PACLITAXEL C/CN

E9 1 PACLITAXEL DIHYDRATE/CN
E10 1 PACLITAXEL SUCCINATE/CN
E11 1 PACLITAXEL-2'-ACETATE/CN
E12 1 PACLITAXEL-3'-14C/CN

=> s e3

L1 1 PACLITAXEL/CN

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 33069-62-4 REGISTRY

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid
deriv.

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-

[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.alpha.,
12.alpha.,12a.alpha.,12b.alpha.]]-

CN Tax-11-en-9-one,

5.beta.,20-epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-
hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with
(2R,3S)-N-benzoyl-3-
phenylisoserine (8CI)

OTHER NAMES:

CN ABI 007

CN BMS 181339-01

CN NSC 125973

CN Paclitaxel

CN Plaxicel

CN Taxol

CN Taxol A

CN Yewtaxan

FS STEREOSEARCH

MF C47 H51 N O14


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, DDFU, DETHERM*,
DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB,
IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PHARMASEARCH,
PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL,

VETU

(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



6727 REFERENCES IN FILE CA (1962 TO DATE)
 365 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 6752 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d rn cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 33069-62-4 REGISTRY

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
 tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
 ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid
 deriv.

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
 dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
 cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-

[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.alpha.,
 12.alpha.,12a.alpha.,12b.alpha.]]-

CN Tax-11-en-9-one,

5.beta.,20-epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-
 hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with

(2R,3S)-N-benzoyl-3-
 phenylisoserine (8CI)

OTHER NAMES:

CN ABI 007

CN BMS-181339-01

CN NSC 125973

CN Paclitaxel

CN Plaxicel

CN Taxol

CN Taxol A

CN Yewtaxan

=> e docetaxel/cn

E1 1 DOCENTAL/CN

E2 1 DOCETAXAL/CN

E3 1 --> DOCETAXEL/CN
E4 1 DOCETAXEL HEMIHYDRATE/CN
E5 1 DOCETAXEL TRIHYDRATE/CN
E6 1 DOCEVITA/CN
E7 1 DOCEYLPENTADECYL ACRYLATE-METHYL ACRYLATE-1-OCTADECENE
POLYM

ER/CN
E8 1 DOCHC/CN
E9 1 DOCHLOXYTHEPIN/CN
E10 1 DOCI/CN
E11 1 DOCIBIN/CN
E12 1 DOCIGRAM/CN

=> s e3

L2 1 DOCETAXEL/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 114977-28-5 REGISTRY

CN Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy)carbonyl]amino]-
.alpha.-hydroxy-,

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-
trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid
deriv.

CN Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy)carbonyl]amino]-
.alpha.-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-

2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-
tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
ester,

[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha. (.alpha.R*,.beta.S
*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-

OTHER NAMES:

CN Docetaxel

CN RP 56976

CN Taxotere

FS STEREOSEARCH

DR 216252-50-5

MF C43 H53 N O14

CI COM

SR CA


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL,
DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*,
MSDS-OHS, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE,

TOXCENTER,

USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry.



1367 REFERENCES IN FILE CA (1962 TO DATE)
 63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1377 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

15.48

15.69

STN INTERNATIONAL LOGOFF AT 12:20:36 ON 20 JAN 2003

Welcome to STN International! Enter x:x

LOGINID:sssptal600dxk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on
STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:05:32 ON 20 JAN 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:05:43 ON 20 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2003 HIGHEST RN 479481-27-1

DICTIONARY FILE UPDATES: 19 JAN 2003 HIGHEST RN 479481-27-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e 4-desacetyl-4-methylcarbonate taxol/cn

E1	1	4-DEOXYWILFORINE/CN
E2	1	4-DESACETOXYVINDOLINE/CN
E3	0 -->	4-DESACETYL-4-METHYLCARBONATE TAXOL/CN
E4	1	4-DESACETYLVINBLASTINE/CN
E5	1	4-DESACETYLVINBLASTINE 3-CARBOHYDRAZIDE/CN
E6	1	4-DESACETYLVINBLASTINE 3-CARBOXYHYDRAZIDE/CN
E7	1	4-DESACETYLVINBLASTINE N-OXIDE/CN
E8	1	4-DESACETYLVINBLASTINE N-OXIDE/CN
E9	1	4-DESACETYLVINBLASTINE N-OXIDE/CN
E10	1	4-DESACETYLVINBLASTINE N-OXIDE/CN

E11 1 4-DESACETYLVINCALEUKOBLASTINE
3-(2-CHLOROETHYL) CARBOXAMIDE/C
N
E12 1 4-DESACETYLVINCALEUKOBLASTINE 3-(2-CHLOROETHYL) CARBOXAMIDE
S
ULFATE/CN

=> s e5

L1 1 "4-DESACETYLPACLITAXEL 4-METHYL CARBONATE"/CN

=> d rn cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 172481-83-3 REGISTRY
CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-12b-
[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
6-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-
4,11-dihydroxy-12b-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-
7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,

[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha. (.alpha.R*,.beta.S*),11.a
lpha.,12.alpha.,12a.alpha.,12b.alpha.]]-

OTHER NAMES:

CN 4-Desacetylpaclitaxel 4-methyl carbonate

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 172481-83-3 REGISTRY
CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-12b-
[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
6-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-
4,11-dihydroxy-12b-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-
7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,

[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha. (.alpha.R*,.beta.S*),11.a
lpha.,12.alpha.,12a.alpha.,12b.alpha.]]-

OTHER NAMES:

CN 4-Desacetylpaclitaxel 4-methyl carbonate


FS STEREOSEARCH

MF C47 H51 N O15

SR CA

LC STN Files: CA, CAPLUS, CASREACT, SYNTHLINE, TOXCENTER, USPAT2,
USPATFULL

Absolute stereochemistry.



9 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 9 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> fil .carb

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

10.78

10.99

FILE 'MEDLINE' ENTERED AT 12:10:29 ON 20 JAN 2003

FILE 'BIOSIS' ENTERED AT 12:10:29 ON 20 JAN 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'BIOTECHDS' ENTERED AT 12:10:29 ON 20 JAN 2003

COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CAPLUS' ENTERED AT 12:10:29 ON 20 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1

L2 9 L1

=> d l9 abs ibib 1-9



L9 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l2 abs ibib 1-9

L2 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS

GI



AB The present invention provides a synergistic method for the treatment of cancer which comprises administering a synergistically, therapeutically effective amt. of: (i) at least agent selected from the group consisting of cytotoxic agents and cytostatic agents, and (ii) a compd. of formula [I; R1 = Cl, Br, CN, substituted Ph, substituted pyridyl; R2 = alkyl, aralkyl; R3, R5 = substituted alkyl, aryl, heterocycle; R4 = H, alkyl; Z1

= CO, SO2, CO2, SO2N(R5); n = 1,2] or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical compn. for the synergistic treatment of cancer which comprises at least one agent

selected from the group consisting of antiproliferative cytotoxic agents and antiproliferative cytostatic agents, a compd. of formula I, and a pharmaceutically acceptable carrier. Synergism was obsd. when non-proliferating tumor cells were treated with diazepam II.cntdot.HCl and paclitaxel (III) simultaneously or when III preceded II.cntdot.HCl.

ACCESSION NUMBER: 2001:730715 CAPLUS
DOCUMENT NUMBER: 135:288636
TITLE: Synergistic methods and compositions for treating cancer using two or more anticancer agents
INVENTOR(S): Lee, Francis Y.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072721	A2	20011004	WO 2001-US9193	20010322
WO 2001072721	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1272193	A2	20030108	EP 2001-920653	20010322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

US 2002002162 A1 20020103 US 2001-817456 20010326
PRIORITY APPLN. INFO.: US 2000-192278P P 20000327
WO 2001-US9193 W 20010322
OTHER SOURCE(S): MARPAT 135:288636

L2 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A method for inhibiting hair loss and/or promoting hair growth in chemotherapy and/or radiation therapy patients wherein the (R)-enantiomer of

4-[[[(cyanoimino)-[(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile is administered prior to, simultaneous with and/or after chemotherapy and/or radiation treatment. There was a remarkable difference between the 1-(R)-enantiomer and the 2-(S)enantiomer in their effect on hair follicle stimulation; in particular the (R)-enantiomer had a faster onset of action

compared to the corresponding (S)-enantiomer. While the IC50 for vasorelaxant potency of the (R)-enantiomer is 47.+- .17 nM vs. 157.+- .35 nM

for the (S)-enantiomer, the hair growth promoting ability of the (R)-enantiomer for producing hair growth within 11 days of treatment is 8 times greater than the corresponding (S)-enantiomer.

ACCESSION NUMBER: 2001:658077 CAPLUS

DOCUMENT NUMBER: 135:205580

TITLE: Method for inhibiting or treating chemotherapy-induced hair loss

INVENTOR(S): Atwal, Karnail S.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 447,002.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001020038	A1	20010906	US 2001-805347	20010313
US 6458835	B2	20021001		
US 6013668	A	20000111	US 1998-119884	19980721
ZA 9807220	A	20000214	ZA 1998-7220	19980812
US 6472427	B1	20021029	US 1999-447002	19991122
US 6262122	B1	20010717	US 2000-615345	20000712
PRIORITY APPLN. INFO.:			US 1997-55568P	P 19970813
			US 1998-71364P	P 19980115
			US 1998-119884	A1 19980721
			US 1999-447002	A2 19991122

L2 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A process for the synthesis of C-4 Me carbonate paclitaxel analog from 10-deacetylbaaccatin III is described by the selective redn. of the acetate

at the C-4 position of 10-deacetylbaaccatin III using Red-A1.

ACCESSION NUMBER: 2001:115139 CAPLUS

DOCUMENT NUMBER: 134:163187

TITLE: Process for the preparation of a paclitaxel C-4 methyl carbonate analog



INVENTOR(S): Kant, Joydeep

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010856	A1	20010215	WO 2000-US21260	20000803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1206461	A1	20020522	EP 2000-952478	20000803
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6248908	B1	20010619	US 2000-635553	20000810
US 2001044549	A1	20011122	US 2001-813085	20010320
US 6353120	B2	20020305		
PRIORITY APPLN. INFO.:			US 1999-148392P	P 19990811
			WO 2000-US21260	W 20000803
			US 2000-635553	A3 20000810
OTHER SOURCE(S):			CASREACT 134:163187	
REFERENCE COUNT: 1			THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE	

FORMAT

L2 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



AB Novel reaction conditions for the cleavage of silyl ethers from silyl protected taxane precursors I {R1 = Me, Ph, 4-Me-, 4-NO2-C6H4, cyclohexyl; R2 = Me, Et, n-Pr, CMe3, Bu, pentyl, Ph, 4-NO2-C6H4, cyclopropyl, cyclobutyl, OMe; R3 = Si[(CHMe2)2]2OMe, SiEt3, SiMe3, SiMe2CMe3; R4 = H, Me, Ph, acetyl, benzoyl, pentanoyl; R5 = (4S,5R)-4,5-dihydro-2,4-diphenyl-5-oxazolecarbonyl, (2R,3S)-R7CH(NHCOR8)CHR6CO-; R6 = H, F, OH, OMe, OSiEt3, OSiMe2CMe3, OCMe2OMe; R7 = Ph, CMe3, CHMe2; R8 = Ph, CMe3, OCMe3, CH3CM3; cyclobutyl, cyclohexyloxy, 2-furyl} to afford the anti-cancer agents paclitaxel and paclitaxel analogs in high yield and quality was described. Paclitaxel was prepd. from a taxane precursor by treating the taxane precursor with a strong acid, such as trifluoroacetic acid, in a solvent such as aq. acetic acid, such that the amt. and no. of side reactions and taxane impurities are significantly minimized. Also described were the crystn. methods for the isolation of paclitaxel in either of the two crystal forms A or B. Thus, taxane silyl ether II was reacted with trifluoroacetic acid and glacial acetic acid in water for

5-7

h., followed by treatment of the unisolated intermediate with sulfuric acid in water to give paclitaxel in 86.9% yield.

ACCESSION NUMBER: 2000:824239 CAPLUS
DOCUMENT NUMBER: 133:362862
TITLE: Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel (Taxol) and paclitaxel analogues
INVENTOR(S): Singh, Ambarish; Weaver, Raymond E., Jr.; Powers, Gerald L.; Rosso, Victor W.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069840	A1	20001123	WO 2000-US12469	20000508
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1178979	A1	20020213	EP 2000-932151	20000508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002544269	T2	20021224	JP 2000-618257	20000508
US 6184395	B1	20010206	US 2000-571234	20000516
PRIORITY APPLN. INFO.: US 1999-134469P P 19990517 WO 2000-US12469 W 20000508				
OTHER SOURCE(S): CASREACT 133:362862; MARPAT 133:362862				
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE				

FORMAT

L2 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A series of 98 paclitaxel analogs were investigated using the comparative mol. field anal. (ComFA) and a high predictive 3D-QSAR model with a significant cross-validated .gamma.cv2, conventional .gamma.2, and predictive .gamma.pred.2 equaling to 0.714, 0.901, 0.812, resp., was obtained. It revealed that the changes of the C-13 side chain groups, esp. 2'-OH, affected the activity significantly and others did less relatively. It also showed that the model was significant for the research and development of novel paclitaxel analogs to reduce the blind flight during drug designing.

ACCESSION NUMBER: 2000:218668 CAPLUS
 DOCUMENT NUMBER: 133:255
 TITLE: Studies on the quantitative structure-activity relationships of paclitaxel analogs
 AUTHOR(S): Shi, Bing-Xing; Liang, Shi-Le; Yuan, Ying-Jin; Sun, Ming; Miao, Fang-Ming
 CORPORATE SOURCE: Department of Biochemical Engineering, Tianjin University, Tianjin, 300072, Peop. Rep. China
 SOURCE: Gaodeng Xuexiao Huaxue Xuebao (2000), 21(3), 401-406
 CODEN: KTHPDM; ISSN: 0251-0790
 PUBLISHER: Gaodeng Jiaoyu Chubanshe
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

L2 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB The semisynthesis and biol. activity of paclitaxel (Taxol) analogs in which the oxygen atom in ring D is substituted by a sulfur or a selenium atom is presented. These derivs. were synthesized and tested in order to make more transparent the role of the oxetane ring in the biol. activity of paclitaxel. The sulfur derivs. were found to be less active than paclitaxel in biol. assays, while the selenium deriv. could not be converted to its 4-acyl analog. The results with the sulfur analogs suggest that the oxygen atom in the oxetane ring plays an important role in the m chanism by which paclitaxel exhibits its anticancer activity.

ACCESSION NUMBER: 1999:202337 CAPLUS
 DOCUMENT NUMBER: 131:5390
 TITLE: Synthesis and Biological Evaluation of Novel


AUTHOR(S): Paclitaxel (Taxol) D-Ring Modified Analogs
Gunatilaka, A. A. Leslie; Ramdayal, Frank D.;
Sarragiotto, Maria H.; Kingston, David G. I.;
Sackett,
CORPORATE SOURCE: Dan L.; Hamel, Ernest
Department of Chemistry, Virginia Polytechnic
Institute and State University, Blacksburg, VA,
24061-0212, USA
SOURCE: Journal of Organic Chemistry (1999), 64(8), 2694-2703
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L2 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS
AB A series of 94 paclitaxel analogs exhibiting antitumor activity by
promoting the assembly of microtubules and inhibiting the disassembly
process of microtubules to tubulin were investigated using the
comparative
mol. field anal. (ComFA) method. These compds. belonging to 10
structural
classes were randomly divided into a training set of 80 compds. and a
test
set of 14 compds. Since the 3-dimensional structure of ligand-receptor
complex is unknown, from x-ray and NMR data, the authors rationally
selected the 3-dimensional structure of paclitaxel in a polar soln. as
the
active conformation and starting structure for mol. modeling, the other
mols. were aligned using this mol. model as the template. The most
optimal ComFA yielded a 2-component model, with significant
cross-validation r^2_{cv} of 0.640 and conventional r^2 of 0.868. The
predictive ability of training set model was tested on the test set of 14
compds. The tests not only revealed the robustness of the ComFA model
but
demonstrated that for this model r^2_{pred} based on the mean activity of
test
set compds. can accurately est. external predictivity but r^2_{pred} based on
the mean activity of training set compds. overestimated the model. The
ComFA model explained why the activity of taxoid is sensitive to the
stereochem. of the atoms at C-2' and C-3' positions and the presence of
hydroxyl group at C-2' position. The other factors affecting activity
were also elucidated according to std. coeff. contour maps of steric and
electrostatic fields derived from the ComFA model.

ACCESSION NUMBER: 1998:31653 CAPLUS
DOCUMENT NUMBER: 128:30043
TITLE: Comparative Molecular Field Analysis of A Series of
Paclitaxel Analogs
AUTHOR(S): Zhu, Qiqing; Guo, Zongru; Huang, Niu; Wang, Minmin;
Chu, Fengming
CORPORATE SOURCE: Department of Synthetic Medicinal Chemistry Institute
of Materia Medica Chinese Academy of Medical
Sciences,
Peking Union Medical College, Beijing, 100050, Peop.
Rep. China
SOURCE: Journal of Medicinal Chemistry (1997), 40(26),
4319-4328
CODEN: JMCMAR; ISSN: 0022-2623

L2 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



ACCESSION NUMBER: 1996:136175 CAPLUS
DOCUMENT NUMBER: 124:289921
TITLE: Synthesis and Biological Evaluation of C-13
Amide-Linked Paclitaxel (Taxol) Analogs
AUTHOR(S): Chen, Shu-Hui; Farina, Vittorio; Vyas, Dolatrai M.;
Doyle, Terrence W.; Long, Byron H.; Fairchild, Craig
CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research
Institute, Wallingford, CT, CONNECTICUT, USA
SOURCE: Journal of Organic Chemistry (1996), 61(6), 2065-70
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:289921

AB A large no. of C-4 paclitaxel analogs have been prepd. in the course of our systematic C-4 modification. These include C-4 esters, carbonates, carbamates as well as a C-4 deacetyl derivs. All of these analogs were evaluated in a tubulin polymn. assay as well as in a cytotoxicity assay against a human colon cancer cell line. The potent analogs emerging from these in vitro assays were further evaluated in vivo. With the exception of paclitaxel side chain bearing C-4 carbamates and C-4 arom. esters,

of the C-4 aliph. esters and carbonates were found to possess comparable or superior activity to paclitaxel in vitro. Several C-4 aliph. esters and carbonates also exhibited in vivo activities against i.p. implanted murine M-109 lung carcinoma.

AUTHOR(S) : agents
Chen, Shu-Hui; Wei, Jian-Mei; Long, Byron H.;

Fairchild, Craig A.; Carboni, Joan; Mamber, Steven
W.;
Rose, William C.; Johnston, Kathy; Casazza, Anna M.;
et al.
CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Res. Inst.,
Wallingford, CT, 06492-7660, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995),
5(22), 2741-6
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

=> s 4-desacetyl-4-methylcarbonate(w)taxol?
L3 1 4-DESACETYL-4-METHYLCARBONATE(W) TAXOL?

=> d l3

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 2002:240547 CAPLUS
DN 136:257231
TI Method for reducing toxicity of combined chemotherapies
IN Minotti, Giorgio; Gianni, Luca
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024179	A2	20020328	WO 2001-US27620	20010906
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
	US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001088805	A5	20020402	AU 2001-88805	20010906
	US 2002049170	A1	20020425	US 2001-954953	20010918
PRAI	US 2000-234496P	P	20000922		
	WO 2001-US27620	W	20010906		

=> d l3 abs ibib

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AB Compns. and methods are provided for use in the treatment of cancer. A
method for the treatment of cancer is provided comprising administration
of 4-desacetyl-4-methylcarbonate
taxol and doxorubicin to a patient in need thereof. Surprisingly,
it has been found that 4-desacetyl 4-Me carbonate taxol does not
stimulate
formation of cardiotoxic metabolic doxorubicin byproducts. Also provided
with the present invention is a chemotherapeutic compn. comprising a
chemotherap utically effective amt. of 4-desacetyl 4-Me carbonate taxol
and doxorubicin. In a further embodiment of the invention, the

chemotherapeutic compn. is disposed within a pharmaceutically acc ptable carrier. Alternatively, each agent, 4-desacetyl 4-Me carbonate taxol and doxorubicin may b formulated sep. to facilitate sequential administration of the compns.

ACCESSION NUMBER: 2002:240547 CAPLUS
DOCUMENT NUMBER: 136:257231
TITLE: Method for reducing toxicity of combined chemotherapies
INVENTOR(S): Minotti, Giorgio; Gianni, Luca
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024179	A2	20020328	WO 2001-US27620	20010906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088805	A5	20020402	AU 2001-88805	20010906
US 2002049170	A1	20020425	US 2001-954953	20010918
PRIORITY APPLN. INFO.:			US 2000-234496P	P 20000922
			WO 2001-US27620	W 20010906

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
40.95	51.94

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-6.51	-6.51

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 12:16:30 ON 20 JAN 2003

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:

LOGINID:ssspta1600dxk

STN INTERNATIONAL LOGOFF AT 11:38:55 ON 30 JAN 2002

Connection closed by remote host

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:ssspta1600dxk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS	3	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS	4	Oct 09	Number of Derwent World Patents Index updates increased
NEWS	5	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS	6	Oct 22	Over 1 million reactions added to CASREACT
NEWS	7	Oct 22	DGENE GETSIM has been improved
NEWS	8	Oct 29	AAASD no longer available
NEWS	9	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS	10	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS	11	Nov 29	COPPERLIT now available on STN
NEWS	12	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS	13	Nov 30	Files VETU and VETB to have open access
NEWS	14	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS	15	Dec 10	DGENE BLAST Homology Search
NEWS	16	Dec 17	WELDASEARCH now available on STN
NEWS	17	Dec 17	STANDARDS now available on STN
NEWS	18	Dec 17	New fields for DPCI
NEWS	19	Dec 19	CAS Roles modified
NEWS	20	Dec 19	1907-1946 data and page images added to CA and Caplus
NEWS	21	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS	22	Jan 25	Searching with the P indicator for Preparations
NEWS	23	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS EXPRESS			August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific